{
  "model": "gemini-flash-latest",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 2,
  "workspacePath": "workspaces/gemini-flash-latest-tumor-vaccine-ici-run-2",
  "success": false,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 169012,
  "agentCostUsd": 0,
  "graderCostUsd": 0,
  "totalCostUsd": 0,
  "agentUsage": {
    "promptTokens": 49689,
    "cachedTokens": 35085,
    "responseTokens": 2877,
    "thinkingTokens": 4151,
    "totalTokens": 56717
  },
  "graderUsage": {
    "promptTokens": 0,
    "cachedTokens": 0,
    "responseTokens": 0,
    "thinkingTokens": 0,
    "totalTokens": 0
  },
  "totalUsage": {
    "promptTokens": 49689,
    "cachedTokens": 35085,
    "responseTokens": 2877,
    "thinkingTokens": 4151,
    "totalTokens": 56717
  },
  "modelVersions": [
    "gemini-flash-latest"
  ],
  "agentFinalText": "### Completion Checklist\nThe following required output files have been successfully written:\n\n*   `output/claim_audit.json`\n*   `output/public_summary.json`\n*   `output/quantitative_findings.json`\n*   `output/study_overview.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse Efficacy (Combination)\",\n      \"sample_size_or_observations\": \"78\",\n      \"description\": \"Tumor-bearing mice pooled across repeat experiments treated with intratumoral mRNA vaccine and anti-PD-L1 combinations.\"\n    },\n    {\n      \"id\": \"human-retrospective-ici\",\n      \"label\": \"Human Retrospective Metastatic\",\n      \"sample_size_or_observations\": \"130\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination acts as a sensitizer, dramatically improving the therapeutic effect of immune checkpoint blockade (ICI) therapy.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"The sensitization effect is dependent on and mediated by local type I interferon signaling, which is triggered by the mRNA platform.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"The mechanism of action involves a strong expansion of the tumor's MHC-I-presented antigen landscape, making the tumor more visible to T cells.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"PD-L1 pathway activity increases following vaccination, creating a stronger rationale for the combination therapy.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"mRNA Vaccines Can Turn 'Cold' Tumors into 'Hot' Targets for Immunotherapy, Study Suggests\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) are powerful cancer drugs but often fail because the tumor is 'invisible' to the immune systemâ€”known as a 'cold' tumor. This study found that injecting an mRNA vaccine directly into the tumor can change this. The vaccine triggers a strong local immune alarm signal (Type I interferon), which acts like a spotlight, forcing the tumor cells to display a wider array of their internal proteins (antigens) on their surface. This change makes the tumor visible to T-cells. Furthermore, this process increases the expression of the checkpoint target (PD-L1), creating a strong rationale for combining the mRNA vaccine with ICI treatment. In mouse models, this combination significantly improved tumor control compared to either treatment alone. Intriguingly, a retrospective analysis of human metastatic patients suggested those who had received a common SARS-CoV-2 mRNA vaccine prior to ICI treatment experienced improved survival. This provides a strong, biologically plausible mechanism for improving immunotherapy but requires larger, planned clinical trials to confirm the human benefit.\",\n  \"what_is_new\": [\n    \"The study demonstrates a novel mechanism where intratumoral mRNA vaccination creates an inflammatory, interferon-rich environment that expands the tumor's presented antigen repertoire.\",\n    \"It quantitatively shows that mRNA treatment significantly increases the breadth of antigens displayed on MHC-I, effectively increasing tumor visibility to T cells.\",\n    \"The results align a successful preclinical mouse model intervention with retrospective improved survival in human patients who received standard-of-care ICI treatment after a systemic SARS-CoV-2 mRNA vaccine.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The positive human survival data comes from a retrospective analysis, meaning it is not a randomized trial and may be affected by unaccounted factors (residual confounding).\",\n    \"The human data involves systemic SARS-CoV-2 vaccination, which is different from the direct intratumoral injection used in the primary mechanistic mouse models.\",\n    \"Variations in tumor types, patient treatment histories, and the timing of vaccination relative to ICI initiation limit the ability to draw direct, causal interpretations.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"ICI (Immune Checkpoint Inhibitor)\",\n      \"definition\": \"A type of drug that blocks proteins (like PD-L1) that cancer cells use to 'switch off' immune responses, thereby allowing the patient's immune system to attack the tumor.\"\n    },\n    {\n      \"term\": \"mRNA Vaccine\",\n      \"definition\": \"A vaccine technology that delivers genetic instructions (mRNA) to cells to produce a specific protein, which then triggers a strong immune response against that protein.\"\n    },\n    {\n      \"term\": \"Antigen Presentation\",\n      \"definition\": \"The essential process by which cells display fragments of proteins (antigens) on their surface using molecules like MHC-I, allowing T-cells to check if the cell is healthy or cancerous.\"\n    },\n    {\n      \"term\": \"Type I Interferon (IFN)\",\n      \"definition\": \"A key signaling molecule released by cells in response to viral invasion or other danger signals, which activates a powerful local and systemic innate immune response.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will prospective, randomized clinical trials confirm the survival benefit seen in the retrospective human cohort and lead to a new standard of care?\",\n    \"What is the optimal route of administration (intratumoral vs. systemic) and timing for the mRNA vaccine to achieve maximum synergistic effect with ICI in patients?\",\n    \"Can this approach be universally applied to all tumor types, or is it restricted to a specific immunological subset of cancers (e.g., 'hot' vs. 'cold' tumors)?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 22,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 8,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 9,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 10,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 11,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-13T17:39:37.035Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-13T17:39:41.061Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-13T17:39:49.702Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-13T17:39:54.761Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-13T17:40:10.789Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-13T17:40:18.027Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-13T17:40:55.468Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-13T17:41:27.825Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-13T17:41:37.969Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T17:42:08.146Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-13T17:42:18.075Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "error": "LLM JSON call failed after 2 attempt(s)"
  }
}
